Plandaí inks deal for distribution of Phyotofare extracts in India

By Hank Schultz

- Last updated on GMT

Plandaí inks deal for distribution of Phyotofare extracts in India
Plandaí Biotechnology, Inc., a company that produces a line of extracts branded as Phytofare, has concluded a deal for the distribution of its ingredients in India.

Under the deal, India company Bal Pharma, a manufacturer and exporter of pharmaceutical finished formulation/bulk drugs and distributor of nutraceuticals ingredients, will use the Plandaí’s Phytofare line of highly bioavailable plant extracts in its finished formulation products while also distributing Phytofare as an active ingredient in its own right throughout India.

“Bal Pharma should quickly be able to generate substantial market penetration for Plandaí. Our agreement with such a highly-regarded Indian company further validates the fifteen years of research that has gone into bringing Phytofare® to market and the solid science behind our phyto-available products,”​ said Callum Cottrell-Duffield, vice president of sales for Plandaí.  Earlier this year the company concluded a deal to put its ingredients into products on shelves in South Africa​.

Tea plantation roots

Plandaí, which has a corporate office in Logan, UT but sources its raw material and does its processing in South Africa, began as an effort to rehabilitate a derelict tea plantation the country. The tea estate had gone to seed, literally, with the bushes allowed to grow into small trees and the processing facilities wrecked.  After a number of years and a hefty infusion of cash, the company reported the rehabilitation process to be complete.

Plandaí has built its business model around a propriety CRS processing and extraction system for live plant materials that alters the isomeric properties of phytonutrients in live plant material and rearranges them in a ratio such that they are significantly better absorbed.  In the case of the tea from the plantation, the leaves are processed within hours of picking.

According to Plandaí, in human tissue antioxidants are normally found in both cis and trans isomer compounds in a 50/50 ratio.

However, flavonoids in green tea might have a 95:5 cis:trans structure, while lycopene in tomatoes usually has a 95:5 trans-to-cis ratio. In both cases, the bioactive components are therefore very poorly absorbed.

Plandaí’s process changes trans-isomers into the cis form (e.g.. for lycopene) or vice versa (changes cis-isomers into the trans form, e.g.. for green tea catechins and citrus limonoids and bioflavanoids), such that the end product is far more bioavailable, representing a step change in the industry, the company has said.

Plandaí has applied its proprietary hydrodynamic extraction process to citrus fruits and plans to test it on cannabis as well.

Related news

Related products

show more

Your Product Innovation Begins Here: Booth 4055

Your Product Innovation Begins Here: Booth 4055

Content provided by Effepharm Ltd | 22-Oct-2024 | Product Brochure

EffePharm will showcase innovative anti-aging solutions, featuring UthPeak™, world’s first self-GRAS approved NMNH, which boosts NAD+ levels by 10X. UthPeak™...

Fueling Athletes with Nature for Peak Performance

Fueling Athletes with Nature for Peak Performance

Content provided by SEPPIC INC | 07-Oct-2024 | White Paper

For many years, pine bark extracts have been harnessed for their potent anti-oxidant and anti-inflammatory properties, delivering a wide array of health...

Related suppliers

Follow us

Products

View more

Webinars